Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
Regdanvimab (CT-P59) (0-1000 ng/mL; 72 h) can neutralize Gamma, Delta and Epsilon variants with IC50s of 161.5-1237 ng/mL[1].
Regdanvimab (CT-P59) (5-80 mg/kg; i.p.; single dose) has an ability to lower viral burden against Gamma and Delta variants in mice[1].
References:
[1]. Ryu DK, et al. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021 Nov 12;578:91-96.